Thymosin Alpha-1 Review 2026: Evidence, Dosage, and the Approved Drug Status

Thymosin Alpha-1 sits in a strange position. It's an approved pharmaceutical in roughly 35 countries. It has Phase 3 clinical trial data. It's been used in thousands of patients for hepatitis, cancer adjuvant therapy (a treatment given after the primary therapy, like surgery or chemotherapy, to enhance its effect and prevent recurrence), and severe COVID-19. It has FDA orphan drug designation (a status granted by the US Food and Drug Administration to incentivize the development of drugs for rare diseases) for several conditions.

And yet if you're reading this in the US, UK, or most of Western Europe, it's a research chemical.

That contradiction isn't because the evidence is weak. It's because the development path in Western markets has been fragmented. The compound has been caught between pharmaceutical business decisions and regulatory timelines rather than failing on scientific merit. This review treats Tα1 as what it is: one of the most clinically validated peptides on this site.

Key Takeaways

• Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus gland
• Sold as Zadaxin (thymalfasin) and approved in \~35 countries for hepatitis B, hepatitis C, and as a cancer treatment adjuvant
• Works as an immunoMODULATOR (a substance that helps regulate or balance the immune system, rather than just increasing its activity), not just an immunostimulant (a substance that increases the activity of the immune system); it regulates immune response rather than blindly boosting it
• Hepatitis B evidence is strongest: seven RCTs (Randomized Controlled Trials) showed significantly higher sustained response rates (the percentage of patients who maintain a positive treatment outcome long after the treatment has ended) than untreated controls
• COVID-19: one study showed Tα1 reduced mortality from 30% to 11.11% in severe cases; but other studies showed mixed or conflicting results
• Safety profile is genuinely clean across over 11,000 patients in more than 30 clinical trials
• NOT the same thing as Thymosin Beta-4 (TB-500). Different peptide, different mechanism, different applications
• Not approved in the US or EU. FDA orphan drug designation exists for some conditions
• Subcutaneous injection only. No oral bioavailability

In Simple Terms

• What the thymus does: The thymus is a small organ behind your breastbone. It's where T cells (the immune system's soldiers) go to school. They learn to recognize threats, distinguish self from non-self, and mature into functional immune cells.
• What happens with age: The thymus starts shrinking after puberty. By age 70, it's mostly replaced by fat tissue. T cell output drops. Your immune system gradually loses its ability to train new recruits. This is called immune senescence, and it's why older people are more vulnerable to infections and cancer.
• What Tα1 does: It's a natural peptide the thymus makes. It helps T cells mature and differentiate (to change from one cell type to a more specialized cell type). It activates natural killer cells (a type of immune cell that can kill virus-infected cells and cancer cells). It improves dendritic cell function (the ability of immune cells, or 'scouts', to present foreign material to T cells). It modulates cytokines (regulates small signaling proteins that control inflammation and immune response). The key word is "modulate." It doesn't just crank up your immune system. It helps regulate and balance it.
• Why that matters: A crude immune booster is dangerous for someone with autoimmune disease. An immune modulator is a different tool; it nudges the system toward proper function rather than just turning the volume up. This distinction is why Tα1 has been studied for conditions where immune regulation (not just stimulation) is the goal.
• The honest evidence summary: Hepatitis data is strong, with approved-drug-level evidence. Cancer adjuvant use has real clinical backing. COVID-19 data is mixed but includes some compelling results in severe cases. Aging and immune senescence is the longevity angle, but that application has the least controlled evidence.

Table of Contents

1. What is Thymosin Alpha-1?
2. The thymus, aging, and immune senescence
3. How it works
4. Thymosin Alpha-1 vs Thymosin Beta-4
5. How do you take it?
6. Dosing
7. What does the evidence show?
8. The East-West approval gap
9. Autoimmune considerations
10. Safety and side effects
11. What happens when you stop?
12. Sourcing and quality
13. Legal and regulatory status
14. Unanswered questions
15. Final take
16. FAQ

What is Thymosin Alpha-1?

Tα1 is a 28-amino-acid peptide originally isolated from thymosin fraction 5 (a crude extract from the thymus gland from which Tα1 was isolated), a bovine thymus extract. It was discovered in the 1960s by Allan Goldstein's group and purified from fraction 5 in 1977, when it was found to possess 10 to 1,000 times higher activity than the crude extract.

The synthetic version is called thymalfasin, sold under the brand name Zadaxin (developed by SciClone Pharmaceuticals). It's identical to the naturally occurring peptide. Tα1 is found in multiple organs including thymus, spleen, lung, kidney, brain, and blood, with the highest concentration in the thymus.

The Thymus, Aging, and Immune Senescence

This section matters because it's the biological foundation the entire Tα1 story rests on.

The thymus is most active during childhood. After puberty, it begins involuting (the process of shrinking back to a smaller size or becoming non-functional); shrinking and being replaced by fatty tissue. By mid-adulthood, thymic output of new T cells has dropped substantially. By old age, the thymus is largely non-functional.

The consequences are real. Fewer naive T cells (T cells that have not yet encountered a specific threat) means your immune system relies more heavily on its existing memory T cell repertoire (the collection of T cells that 'remember' past infections, providing long-term immunity). The ability to respond to new threats declines. Cancer surveillance weakens. Vaccine responses become less robust.

Tα1 is mechanistically connected to compensating for this decline. It doesn't regrow the thymus. But it promotes T cell maturation and differentiation from the remaining thymic and peripheral precursors (cells outside the thymus that can still develop into mature T cells), partially restoring some of the immune education capacity that's been lost.

How Tα1 Works

T Cell Maturation and Differentiation

This is the primary mechanism. Tα1 promotes the production and maturation of T cells, stimulates Th1 cytokine production (interferon-gamma, interleukin-2), and activates natural killer cell-mediated cytotoxicity (the ability of certain immune cells, like natural killer cells, to kill other cells). In COVID-19 patients, it increased thymus output as measured by T cell receptor excision circles (TRECs) (small circles of DNA created in the thymus during the maturation of T cells, used as a marker for new T cell output) and reversed T cell exhaustion markers (PD-1 and Tim-3) (proteins on T cells that indicate the cell is worn out and less effective at fighting infection).

Toll-Like Receptor (TLR) Signaling (a system where immune sensors (TLRs) detect foreign threats (pathogens) and trigger an immune response)

TLRs are sensors on immune cells that detect pathogens. Tα1 binds to TLR3, TLR4, TLR7, and TLR9, activating downstream signaling pathways (a sequence of molecular events inside a cell triggered by a receptor being activated) (IRF3, NF-κB, p38MAPK) (Intracellular proteins that transmit signals to the cell nucleus, leading to changes in gene expression) that promote immune cell proliferation and activation. This is how it enhances both innate and adaptive immunity (Innate immunity is the non-specific, immediate defense; adaptive immunity is the specific, long-term defense).

Dendritic Cell Activation

Dendritic cells are the immune system's scouts; they find threats and present them to T cells. Tα1 promotes dendritic cell differentiation and the expression of activation markers.

Modulation vs Stimulation

Here's the critical distinction. Tα1 doesn't just increase immune activity indiscriminately. It upregulates MHC Class I expression (Increases the display of marker proteins (MHC Class I) on cell surfaces, which helps T cells recognize threats), stimulates regulatory T cell activity (the function of T cells that suppress or regulate the immune response to prevent excessive or autoimmune reactions), and balances pro-inflammatory and anti-inflammatory cytokine production (the creation of signaling proteins that either promote inflammation (pro-) or reduce inflammation (anti-)). That's regulation, not just amplification. This is why Tα1's side effect profile is dramatically cleaner than other immune modulators like interferon or IL-2.

Thymosin Alpha-1 vs Thymosin Beta-4

This confusion is everywhere. Let's end it.

Thymosin Alpha-1: 28 amino acids. Immune modulation. Promotes T cell maturation. Approved drug for hepatitis and cancer adjuvant therapy. The compound reviewed on this page.

Thymosin Beta-4 (TB-500's parent compound): 43 amino acids. Tissue repair. Promotes cell migration, wound healing, and angiogenesis. Used in the peptide community for injury recovery. A completely different compound with a completely different function.

Both were isolated from thymosin fraction 5 (the same thymus extract). That's where the similarity ends. Different peptides, different mechanisms, different applications. TB-500 won't help your immune system. Tα1 won't heal your torn tendon.

How Do You Take Thymosin Alpha-1?

Subcutaneous injection only. Tα1 is a peptide and gets degraded in the GI tract; oral administration doesn't work. In approved clinical protocols, it's injected subcutaneously (typically the arm or abdomen).

Pharmacokinetics (the study of how a drug is absorbed, distributed, metabolized, and eliminated by the body): peak blood concentration at 1 to 2 hours after subcutaneous injection, with a plasma half-life (the time it takes for the concentration of a drug in the blood plasma to be reduced by half) of approximately 2 to 3 hours.

Thymosin Alpha-1 Dosing

Approved clinical protocols (Zadaxin): 1.6 mg subcutaneously twice weekly is the standard dosing in hepatitis treatment. Treatment duration is typically 6 months for hepatitis B. Patients under 40 kg are adjusted to 40 mcg/kg twice weekly.

COVID-19 protocols used in China: 1.6 mg daily or twice daily for 5+ days in severe cases.

Cancer adjuvant protocols: 1.6 mg twice weekly alongside chemotherapy regimens, for varying durations depending on the treatment protocol.

Talk to a clinician. These are approved pharmaceutical dosing protocols, not community guesswork.

What Does the Thymosin Alpha-1 Evidence Show?

Hepatitis B and C (Strongest Evidence)

Seven randomized controlled studies on Tα1 monotherapy for chronic hepatitis B showed that 6 months of treatment (1.6 mg twice weekly) produced significantly higher sustained virological response rates (the rate at which the virus levels in the body are reduced or eliminated by the treatment) than untreated controls. An RCT of 98 patients with chronic hepatitis B confirmed these findings.

Important clinical nuance: the benefits of Tα1 therapy are usually not immediately apparent during treatment. Response tends to accumulate gradually after therapy ends. This delayed response pattern is different from direct antivirals and is consistent with immune-mediated viral clearance.

Tα1 was also effective in combination with interferon-alpha for hepatitis C. This is the evidence base that led to approved drug status in approximately 35 countries.

Cancer Adjuvant Use

Tα1 is approved as a cancer treatment adjuvant in several markets. It's used alongside chemotherapy to restore chemotherapy-suppressed immune function. The compound potentiates cytokine action (enhances the effect of immune signaling proteins that control immune responses) and reduces the hematological toxicity (harmful effects of a treatment on the blood cell forming system) of cytotoxic drug therapy.

COVID-19

This is where the data gets complicated.

Positive findings: Liu et al. (2020, Clinical Infectious Diseases) showed Tα1 reduced mortality from 30% to 11.11% in 76 severe COVID-19 patients, restored lymphocyte counts (a measure of the number of white blood cells (lymphocytes) in the blood), and reversed T cell exhaustion. Wu et al. found Tα1 reduced 28-day mortality (HR 0.11) (Hazard Ratio of 0.11, meaning the risk of death was reduced by 89% compared to the control group) in critical patients, especially those over 64 years.

Conflicting findings: A larger multicenter cohort study (a research study involving many hospitals or institutions (multicenter) that follows a large group of people (cohort) over time) of 2,282 patients found crude outcomes were actually worse in the Tα1 group, though this likely reflects confounding (an error in a study where an external factor distorts the true relationship between the treatment and the outcome). After adjusting for disease severity, the benefit was seen primarily in patients treated early.

Meta-analysis: A systematic review (a research paper that summarizes and critically evaluates the results of multiple published studies on a specific topic) of 9 studies covering 5,352 patients found conflicting results overall, but subgroup analysis showed benefit in severe/critical patients, especially those over 60.

The honest assessment: Tα1 may genuinely help in severe COVID-19 with immune paralysis, but the evidence is mixed and study quality varies. Large-scale, properly designed RCTs are needed.

Sepsis

Tα1 has been studied for sepsis-induced immune paralysis (a state where the immune system becomes unresponsive or ineffective, often seen in severe infections like sepsis). A multicenter RCT showed it could lower short-term all-cause mortality and improve immune function in severe sepsis patients.

Vaccine Adjuvant

Tα1 has been studied as a vaccine response enhancer, particularly in elderly and immunocompromised populations who respond poorly to standard vaccination. It can enhance T cell-dependent antibody production (the creation of protective proteins (antibodies) by B cells that requires help from T cells).

The East-West Approval Gap of Thymosin Alpha-1

This gap is more clinically significant than the equivalent gap for Semax or Selank. Tα1 has Phase 3 data, decades of approved clinical use, and a safety record across thousands of patients. The FDA hasn't approved it not because it failed trials but because the US development path (originally through Alpha 1 Biomedicals, then SciClone Pharmaceuticals) was fragmented by business decisions rather than scientific failure.

The FDA did grant orphan drug designation for hepatocellular carcinoma (the most common type of liver cancer), malignant melanoma (a serious type of skin cancer), chronic active hepatitis B (a long-term liver infection caused by the Hepatitis B virus that is currently causing inflammation and damage), and DiGeorge syndrome (a genetic disorder that often causes a dysfunctional or missing thymus gland, leading to immune problems). Orphan drug designation is not the same as approval; it means the FDA recognized enough evidence to incentivize development for rare conditions.

What "approved in 35 countries" means for a Western reader: it means regulatory agencies with their own review processes (Italy's AIFA, China's NMPA (Italian and Chinese government bodies that regulate drugs), multiple Southeast Asian authorities) independently concluded the evidence warranted approval. It doesn't mean the evidence meets FDA's specific bar, which has its own requirements around US-conducted trials and statistical endpoints.

Thymosin Alpha-1 Autoimmune Considerations

Tα1 modulates rather than purely stimulates, which changes the risk profile compared to crude immune boosters. But immune modulation in someone with an existing autoimmune condition is not risk-free.

Tα1 is contraindicated (a specific condition or factor that serves as a reason to withhold a certain medical treatment due to the harm that it would cause) in immunosuppressed patients (such as organ transplant recipients on immunosuppressive drugs) unless the benefits clearly outweigh the risks. For autoimmune conditions, the concern is that enhancing immune function could potentially flare the autoimmune component.

The clinical data doesn't show significant autoimmune flares, but the studies were conducted in hepatitis and cancer patients, not autoimmune populations. If you have an autoimmune condition, this conversation belongs with your physician.

Safety and Side Effects of Thymosin Alpha-1

The safety profile is genuinely excellent by any standard. Across over 11,000 patients in more than 30 clinical trials, Tα1 was well tolerated.

Common side effects: injection site redness, irritation, and discomfort. Rare: transient muscle atrophy (temporary wasting or shrinking of muscle tissue), joint aches, hand swelling and rash.

Compare this to other immune modulators: interferon-alpha causes flu-like symptoms, fatigue, depression, and hematological toxicity. IL-2 causes capillary leak syndrome (a condition where fluid and proteins leak out of tiny blood vessels (capillaries), leading to low blood pressure and swelling). Tα1's side effect profile is dramatically cleaner. This favorable toxicity profile has been confirmed across hepatitis, cancer, melanoma, and infectious disease populations.

What Happens When You Stop Thymosin Alpha-1?

No dependency. No withdrawal. No rebound immunosuppression (a severe reduction in immune function after stopping a treatment that was boosting it). Immune function returns to baseline. The hepatitis data actually shows that virological response continues to accumulate after therapy ends, suggesting the immune education Tα1 provides persists beyond the treatment period.

Sourcing and Quality of Thymosin Alpha-1

For Western readers buying outside approved pharmaceutical markets: the gap between Zadaxin (pharmaceutical-grade, manufactured under GMP standards (Good Manufacturing Practice, a system for ensuring products are consistently produced and controlled according to quality standards), verified potency) and research-chemical versions is significant.

Tα1's clinical reputation makes it a target for counterfeiting. If you're sourcing injectable Tα1 as a research chemical, require third-party COA (Certificate of Analysis, a document from an independent lab certifying the purity and composition of a product) with peptide purity, sequence verification, and endotoxin testing (a test to check for harmful bacterial toxins (endotoxins) that can cause fever or shock if injected). The counterfeit risk is real given the compound's established market value.

Legal and Regulatory Status of Thymosin Alpha-1

Approved markets: Zadaxin is approved in approximately 35 countries including Italy, China, and much of Southeast Asia for hepatitis B, hepatitis C, and cancer adjuvant therapy.

US: Not FDA-approved as a drug. FDA orphan drug designation for specific conditions. Available through compounding pharmacies and research peptide suppliers.

EU/UK: Not approved. Research chemical status.

ClinicalTrials.gov: Registered studies exist for COVID-19 and other indications.

Unanswered Questions

1. Will FDA approval ever follow? The COVID-19 data and existing global approvals create momentum, but someone needs to fund and execute US-standard trials.
2. What's the optimal dosing for immune senescence in aging? The approved dosing (1.6 mg twice weekly) is for hepatitis. Whether the same protocol is optimal for age-related immune decline is unknown.
3. Does Long COVID represent a real application? The immune dysregulation (an abnormality or imbalance in the immune system's control and function) of Long COVID is mechanistically logical for Tα1, but controlled data doesn't exist.
4. How much does thymus involution limit Tα1's effectiveness in very old patients? If the thymus is mostly gone, does Tα1 still have enough substrate to work with?

Final Take

Thymosin Alpha-1 has one of the strongest evidence bases on this site alongside semaglutide. Approved drug in 35+ countries. Real Phase 3 trial data. Decades of clinical use across over 11,000 patients with an excellent safety profile. COVID-19 data that's imperfect but shows real signal in severe cases.

The FDA gap is a regulatory and commercial story, not an evidence story. The compound is clinically serious in a way that most peptides on this site simply are not.

If you're considering Tα1 for immune support, go in understanding that the hepatitis and cancer adjuvant evidence is strong, the COVID-19 evidence is mixed, and the aging/immune senescence angle is mechanistically compelling but clinically unproven. And source carefully; the gap between pharmaceutical Zadaxin and research-chemical Tα1 is not trivial.

FAQ

What is Thymosin Alpha-1?

A 28-amino-acid peptide from the thymus gland that modulates immune function. Sold as Zadaxin in approved markets.

Is it the same as TB-500?

No. Completely different peptide with a completely different mechanism. TB-500 (Thymosin Beta-4) is for tissue repair. Tα1 is for immune modulation.

Is it FDA-approved?

No. It has FDA orphan drug designation for specific conditions but is not approved as a drug in the US.

What's the strongest evidence for?

Chronic hepatitis B. Seven RCTs with significantly higher response rates than controls. This is the evidence that led to drug approval in \~35 countries.

Did it help with COVID-19?

Mixed results. Some studies showed significant mortality reduction in severe cases. Others didn't. Subgroup analysis suggests the most benefit in older patients with severe disease.

Is it safe?

Among the safest immune-modulating compounds studied. Over 11,000 patients across 30+ trials. Main side effect is injection site irritation.

Should people with autoimmune disease use it?

Caution warranted. Tα1 modulates rather than blindly stimulates, but immune modulation in autoimmune patients requires medical supervision.

How is it dosed?

1.6 mg subcutaneously twice weekly is the standard approved protocol for hepatitis. Other conditions use different schedules.